NexImmune is a clinical-stage biotechnology company developing an approach to immunotherapy designed to employ the body's own T cells to generate a specific immune response that mimics natural biology. Co. has two product candidates: NEXI-001 in acute myeloid leukemia, and NEXI-002 in multiple myeloma. Co.'s product candidates are adoptive T cell therapies (ACTs) that contain populations of naturally occurring CD8+ T cells that recognize a defined set of disease-relevant antigen targets. In addition to its programs using the Artificial Immune Modulation (AIM) ACT adoptive cell therapy modality, Co. is also developing an off-the-shelf injectable modality, which it refers to as AIM INJ. The NEXI average annual return since 2021 is shown above.
The Average Annual Return on the NEXI average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NEXI average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NEXI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|